Abstract
Live oral rotavirus (RV) vaccines are part of routine childhood immunization but are associated with adverse effects, particularly intussusception. We have developed a non-live combined RV - norovirus (NoV) vaccine candidate consisting of human RV inner-capsid rVP6 protein and NoV virus-like particles. To determine the effect of delivery route on induction of VP6-specific protective immunity, BALB/c mice were administered a vaccine containing RV rVP6 intramuscularly, intranasally or a combination of both, and challenged with murine RV. At least 65 % protection against RV shedding was observed regardless of delivery route. The levels of post-challenge serum VP6-specific IgA titers correlated with protection.
MeSH terms
-
Administration, Intranasal
-
Animals
-
Antibodies, Viral / immunology
-
Antigens, Viral / administration & dosage
-
Antigens, Viral / genetics
-
Antigens, Viral / immunology*
-
Capsid Proteins / administration & dosage
-
Capsid Proteins / genetics
-
Capsid Proteins / immunology*
-
Female
-
Humans
-
Immunoglobulin G / immunology
-
Mice
-
Mice, Inbred BALB C
-
Rotavirus / genetics
-
Rotavirus / immunology*
-
Rotavirus Infections / immunology
-
Rotavirus Infections / prevention & control*
-
Rotavirus Infections / virology
-
Rotavirus Vaccines / administration & dosage
-
Rotavirus Vaccines / genetics
-
Rotavirus Vaccines / immunology*
Substances
-
Antibodies, Viral
-
Antigens, Viral
-
Capsid Proteins
-
Immunoglobulin G
-
Rotavirus Vaccines
-
VP6 protein, Rotavirus